PerMe

PERME is a deep-tech digital health platform that develops disruptive innovation in home testing with a Novel IP. PERME converts biological samples to digital information in real-time with an affordable device no labs need. With a market potential surpassing $500 billion, its innovative approach is guided by experts in nanotechnology, MEMS (Micro-Electro-Mechanical Systems), longevity, genetics, RF engineering, bioinformatics, and tech entrepreneurs. The company's software initially converts biological data into digital output resulting in health recommendations and telehealth consultations.. Applying advanced data analytics and AI/ML on the big data PerMe is collecting, will be the heart of healthcare innovation, understanding complex diseases and discovering new medicines.

PerMe has raised $2M in total funding across 2 rounds. The company is currently at the Pre-Seed stage. Key investors include Rhodium, IL Angel Club LTD.

PerMe was founded in 2022 by Yoav Rapaport (Founder & CEO).

PerMe operates in Health Tech & Life Sciences, Digital Healthcare, Patient Remote Monitoring, Digital Medical Diagnostics, with core technologies in Artificial Intelligence, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

PerMe is based in Maskit St, Herzliya, Israel, Center District.